Meeting Posters (ICAAC)

55th ICAAC, San Diego, September 2015

Reference No.

Document title

Authors

A-471

Pharmacodynamics of aztreonam against E.coli studied in an in vitro model of infection

 

C Ramsey, KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, A P MacGowanA-472

Pharmacodynamics of Ceftaroline Against Proteus mirabilis
Pre-clinical Clinical Correlates

 

A. Noel, K. Bowker, S. Tomaselli, M. Attwood, A. MacGowanA-497

Pharmacodynamics of minocycline plus rifampicin against S.aureus studied in an in vitro model of infection

 

KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowanA-506

Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftolozane (TOL) in Combination with Tazobactam (TAZ) against Enterobacteriaceae

 

KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowan

 

54th ICAAC, Washington DC, September 2014

Reference No.

Document title

Authors

A-040

Pharmacodynamics of Minocycline against Acinteobacter baumannii studied in a pharmacokinetic Model of Infection

 

KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowanA-042

Pharmacodynamics of Amikacin against Aerobic Gram-negative Rods studied in an in vitro Model of Infection

 

AR Noel, KE Bowker, SG Tomaselli, D Nicholls, AP MacGowanA-1347

Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae established in an in vitro pharmacokinetic model of infection-1347

 

KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan

A-1182Pharmacodynamics of ceftolozane/tazobactam against P.aeruginosa (PSA) Studied in an In Vitro Model of Infection.KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan

A-1347a

Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae
established in an in vitro pharmacokinetic model of infection

 

AP MacGowan, AR Noel, SG Tomaselli, D Nicholls, KE Bowker

 

53rd ICAAC, Denver, September 2013

Reference No.

Document title

Authors

A-1015

Pharmacodynamics of minocycline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection

 

AR Noel, KE Bowker, SG Tomaselli, , AP MacGowan, WW HopeA-1029

Pharmacodynamics of ceftolozane/tazobactam against Gram-negative bacilli

 

KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowanA-022

Pharmacodynamics of Glycopeptides in Combination with Rifampicin for Methicillin Resistant Staphylococcus aureus (MRSA) Infections

 

J . Sharp , J. Livermore, L. Gregson, J. Goodwin, A.P. MacGowan, W.W. HopeA-464

fT>MIC Targets May Vary for Cephalosporins Within the Enterobacteriaceae Group

 

Karen E Bowker, Alan R Noel,1 Jane Ambler, Alasdair P MacGowanA-009

Pharmacodynamics of single dose Oritavancin against Staphylococcus aureus

 

KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowan

 

52nd ICAAC, San Francisco, September 2012

Reference No.

Document title

Authors

A-024

Pharmacodynamics of doripenem against Pseudomonas aeruginosa and Acinetobacter spp

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-628

Assessment of the Antistaphylococcal Effect of Ceftaroline in
Long Duration Human Dose Simulations: Impact of MIC

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-629

Pharmacodynamics of Ceftaroline against Enterobacteriaceae

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-631

The pharmacodynamics of Avibactam (NXL104) in Cobination with Either Ceftaroline or Ceftazidime against Blactamase producing Enterobacteriaceae

 

AR Noel, SG Tomaselli, DL Nicholls, KE Bowker, G Williams, AP MacGowanA-642

Pharmacodynamics of piperacillin-tazobactam (P/T) against Pseudomonas aeruginosa: antibacterial effect and risk of emergence of resistance

 

AR Noel, KE Bowker, AP MacGowanD-763

Colistin MIC Testing: The Effect of Different Types of Microtitre Trays and Surfactant Tween 80 in Broth Microdilution Method

 

E Sweeney, S Nelson, A Lovering, K BowkerE-793

Bactericidal Activity of Multiple Combinations of Fosfomycin and Colistin against NDM-1 producing Enterobacteriaceae

 

KE Bowker, AP MacGowan

 

51st ICAAC, Chicago, Sep 2011

Reference No.

Document title

Authors

A2-556

Pharmacodynamics of Avibactam Plus Either Ceftaroline or Ceftazidime Against an AmpC-Producing Enterobacter spp

 

AR Noel, KE Bowker, AP MacGowan, G WilliamsA2-557

Pharmacodynamics of Ceftaroline Plus Avibactam Against Enterobacteriaceae Studied in an In Vitro Pharmacokinetic Model of Infection

 

K.E. Bowker, A.R. Noel, S.G. Tomaselli, A.P. MacGowan, G. WilliamsA1-1159/6

Pharmacokinetics and Safety of Daptomycin in Young Infants

 

P Brian Smith, Michael Cohen-Wolkowiez, Kevin Watt, Daniel K Benjamin Jr.E-721

Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1 producing Enterobacteriaceae

 

M. Albur, A. Noel, K. Bowker, A. MacGowanA2-555

Pharmacodynamics of Ceftaroline against Staphylococcus aureus
Studied in an In Vitro Pharmacokinetic Infection Model

 

Alan R Noel, Karen E Bowker, Sharon G Tomaselli, Alasdair P MacGowanC2-093

Community-based Nasal Screening Poorly Predicts pvl Carriage and Antimicrobial Resistance in Communityacquired
S.aureus Infection

 

A. Lovering, J. Sunderland, E. Woodward, J Steer, A. Hidalgo-ArroyoF1-314

A monobactam plus double b-lactamase inhibitor combination (BAL30376) designed to overcome multiple resistance in Gram-negative bacilli: proof of concept in an in vitro pharmacokinetic model

 

KE Bowker, AR Noel, AP MacGowan

 

50th ICAAC, Boston, Sep 2010

Reference No.

Document title

Authors

A1-673

Changes in Streptococcus pneumoniae population profiles after
exposure to fluoroquinolones in prolonged dosing simulations

 

KE.Bowker, AR.Noel, HC.Elliott, SG.Tomaselli and AP.MacGowanA1-1383

Pharmacodynamics of Razupenem (PTZ601) against Enterobacteriaceae

 

KE. Bowker, AR. Noel, SG. Tomaselli, HC. Elliott, AP. MacGowanA1-1367

The magnitude of the pharmacodynamic index required for a 24h bacteriostatic effect for S.aureus is associated with increased risk of resistance

 

KE. Bowker, AR. Noel, HC. Elliott, SG. Tomaselli and AP. MacGowanA1-1377

Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftaroline in Combination With NXL104 Against Enterobacteriaceae

 

K. Bowker, A. Noel, H. Elliott, S. Tomaselli, A. MacGowanA1-1382

Pharmacokinetic-Pharmacodynamic Basis for CLSI Carbapenem Susceptibility Breakpoint Changes

 

Sujata M. Bhavnani, Michael N. Dudley, Cornelia Landersdorfer, George L. Drusano, William A. Craig, Ronald N. Jones, Paul G. Ambrose

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk